NeuroOne Medical Technologies Corporation (NMTC)

NeuroOne Medical Technologies Corporation develops and commercializes thin film electrode technology for neurological disorders. Their strategic partnership with RBC Medical Innovations aims to create a radio frequency ablation generator for precise brain tissue ablation.

47/100 AI Score MCap 43M Vol 447K

Company Overview

CEODavid A. Rosa
Employees17
HeadquartersEden Prairie, MN, US
IPO Year2018

NeuroOne Medical Technologies pioneers thin-film electrode technology for neurological solutions, targeting a multi-billion dollar market. With a strategic partnership to advance ablation technology, NeuroOne offers a compelling investment in innovative medical devices poised to transform treatment for epilepsy, Parkinson's, and other neurological disorders.

Investment Thesis

NeuroOne Medical Technologies Corporation presents a compelling investment opportunity due to its innovative thin-film electrode technology and strategic focus on neurological disorders. The company's partnership with RBC Medical Innovations to develop a radio frequency ablation generator is a key value driver, potentially streamlining procedures and improving patient outcomes. With a market capitalization of $0.04 billion, NeuroOne offers significant upside potential as it commercializes its technology and expands its market reach. The company's products target a large and growing market for neurological treatments, including epilepsy, Parkinson's disease, and chronic pain. Successful commercialization of its ablation technology and expansion of its product portfolio could drive significant revenue growth in the coming years. Investors should consider NMTC for its disruptive technology and potential to transform neurological treatments.

Key Highlights

  • Market Cap of $0.04B indicates a small-cap company with potential for high growth.
  • Gross Margin of 56.5% demonstrates strong pricing power and efficient cost management.
  • Strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator enhances product offerings.
  • Focus on thin film electrode technology positions NeuroOne as an innovator in neurological solutions.
  • P/E ratio of -8.69 reflects current losses but also potential for future profitability.

Competitors

Strengths

  • Innovative thin film electrode technology.
  • Strategic partnership with RBC Medical Innovations.
  • Focus on a growing market for neurological disorder treatments.
  • Potential for minimally invasive solutions.

Weaknesses

  • Small market capitalization.
  • Limited commercialized products.
  • Reliance on strategic partnerships.
  • Negative P/E ratio indicating current losses.

Catalysts

  • Upcoming: Completion of development for radio frequency ablation generator with RBC Medical Innovations.
  • Ongoing: Clinical trials and data generation to support product efficacy.
  • Ongoing: Expansion of strategic partnerships to broaden product offerings.
  • Upcoming: Regulatory approvals for new medical devices.

Risks

  • Potential: Competition from established medical device companies.
  • Potential: Regulatory delays in obtaining approvals for new products.
  • Ongoing: Dependence on strategic partnerships for product development.
  • Ongoing: Financial losses and need for additional funding.
  • Potential: Product liability claims.

Growth Opportunities

  • Expansion of Ablation Technology: NeuroOne's partnership with RBC Medical Innovations to develop a radio frequency ablation generator presents a significant growth opportunity. The market for ablation technologies is expanding, driven by the demand for minimally invasive surgical procedures. Successful development and commercialization of this technology could lead to increased revenue and market share for NeuroOne. The timeline for commercialization is estimated within the next 2-3 years, targeting a potential market size of hundreds of millions of dollars.
  • Strategic Partnerships: NeuroOne can pursue additional strategic partnerships to expand its product offerings and market reach. Collaborating with other medical device companies or research institutions could accelerate the development of new technologies and access new markets. These partnerships could focus on areas such as neurostimulation, diagnostics, or drug delivery, broadening NeuroOne's portfolio and revenue streams. The timeline for securing such partnerships is ongoing, with the potential to significantly impact growth within the next 1-2 years.
  • Geographic Expansion: NeuroOne has the opportunity to expand its geographic presence beyond the United States. Entering international markets, such as Europe and Asia, could significantly increase its customer base and revenue potential. This expansion could be achieved through direct sales, distribution agreements, or partnerships with local companies. The timeline for international expansion is estimated within the next 3-5 years, targeting regions with high demand for advanced neurological treatments.
  • Product Diversification: NeuroOne can diversify its product portfolio by developing new applications for its thin-film electrode technology. This could include expanding into areas such as spinal cord stimulation, deep brain stimulation, or neural interfaces. By offering a wider range of products, NeuroOne can cater to a broader customer base and increase its revenue streams. The timeline for product diversification is ongoing, with new product launches expected within the next 2-4 years.
  • Clinical Data Generation: Investing in clinical studies to generate robust data supporting the efficacy and safety of its products is crucial for driving adoption and market penetration. Positive clinical data can enhance NeuroOne's credibility, attract new customers, and support regulatory approvals. These studies can focus on specific applications of its technology, such as epilepsy monitoring or pain management, providing compelling evidence for its benefits. The timeline for generating and publishing clinical data is ongoing, with results expected within the next 1-3 years.

Opportunities

  • Expansion of ablation technology.
  • Strategic partnerships for product development.
  • Geographic expansion into international markets.
  • Diversification of product portfolio.

Threats

  • Competition from larger medical device companies.
  • Regulatory hurdles for new medical devices.
  • Technological advancements by competitors.
  • Potential for product liability claims.

Competitive Advantages

  • Proprietary thin film electrode technology.
  • Strategic partnership with RBC Medical Innovations.
  • Focus on specialized neurological applications.
  • Intellectual property protection through patents.

About

NeuroOne Medical Technologies Corporation, headquartered in Eden Prairie, Minnesota, is a medical technology company focused on developing and commercializing advanced thin film electrode technology. The company's core mission is to provide innovative solutions for patients suffering from a range of neurological disorders, including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. NeuroOne's technology is designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation procedures. Founded with the vision of revolutionizing neurological treatments, NeuroOne has strategically focused on thin-film electrode technology due to its potential for enhanced precision and minimally invasive procedures. The company's product development efforts are centered around creating solutions that improve patient outcomes and reduce the risks associated with traditional surgical interventions. A key aspect of NeuroOne's strategy is its partnership with RBC Medical Innovations, which aims to develop a radio frequency ablation generator that can be used with NeuroOne's combination recording and ablation electrodes. This collaboration is expected to streamline procedures by allowing physicians to record brain activity and ablate brain tissue using a single electrode. NeuroOne's commitment to innovation and strategic partnerships positions it as a key player in the evolving landscape of neurological medical devices. The company's focus on addressing unmet needs in the treatment of neurological disorders underscores its potential for long-term growth and value creation.

What They Do

  • Develop thin film electrode technology.
  • Focus on solutions for neurological disorders.
  • Create devices for continuous electroencephalogram (cEEG) recording.
  • Develop devices for stereoelectroencephalography (sEEG) recording.
  • Work on spinal cord stimulation technology.
  • Develop brain stimulation solutions.
  • Create ablation solutions for neurological disorders.
  • Partner with RBC Medical Innovations for radio frequency ablation generator.

Business Model

  • Develop and sell thin film electrode technology.
  • Partner with other companies to expand product offerings.
  • Generate revenue through sales of medical devices.
  • Focus on solutions for neurological disorders.

Industry Context

NeuroOne Medical Technologies operates within the medical device industry, specifically targeting the neurological disorder treatment market. This market is characterized by increasing demand for minimally invasive procedures and advanced technologies. The competitive landscape includes companies focused on neuromodulation, neurosurgery, and diagnostic tools. NeuroOne's thin-film electrode technology and strategic partnership for ablation solutions position it to capture a share of this growing market. The global market for neurostimulation devices, for example, is projected to reach billions of dollars in the coming years, driven by an aging population and increasing prevalence of neurological disorders.

Key Customers

  • Hospitals and medical centers.
  • Neurologists and neurosurgeons.
  • Patients suffering from neurological disorders.
  • Research institutions.
AI Confidence: 71% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q4 2025 $3M -$1M $0.00
Q3 2025 $3M -$2M $0.00
Q2 2025 $2M -$2M $0.00
Q1 2025 $1M -$2M $0.00

Source: Company filings

Chart & Info

Price Chart

NeuroOne Medical Technologies Corporation (NMTC) stock price: $0.85 (-0.00, -0.40%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future, indicating potential growth ahead.
  • •Community sentiment has shifted positively, with discussions highlighting the innovative nature of NeuroOne's technology and its applications.
  • •Increased media coverage has raised awareness about the company's advancements, attracting interest from potential investors.
  • •Partnerships with medical institutions are being viewed favorably, enhancing credibility and potential market reach.

Why Bear

  • •Concerns over the competitive landscape are growing, as new entrants in the medical technology space could challenge NeuroOne's market position.
  • •Some community members express skepticism about the timeline for product commercialization, fearing delays could impact investor sentiment.
  • •Recent earnings reports have not met expectations, leading to doubts about the company's short-term financial health.
  • •Market volatility and broader economic concerns may overshadow company-specific positives, creating a bearish outlook among some traders.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
446,227

Rationale

AI-generated technical analysis for NMTC including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss NeuroOne Medical Technologies Corporation (NMTC) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for NMTC.

Make a Prediction

Set your price target for NeuroOne Medical Technologies Corporation (NMTC), choose a timeframe, and track your prediction accuracy.

Current price: $0.85

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMTC.

Price Targets

Wall Street price target analysis for NMTC.

Insider Flow (30d)

Mills Jason Richard
Insider
2 months ago
BOUGHT
12,564 shares

MoonshotScore

46.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 6/100

    Gross margin of 22.0% is acceptable but leaves limited room for R&D and marketing investment.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates NMTC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does NeuroOne Medical Technologies Corporation do?

NeuroOne Medical Technologies Corporation is a medical technology company that develops and commercializes thin film electrode technology for the treatment of neurological disorders. Their primary focus is on creating solutions for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation procedures. The company's strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator is a key component of their business model, allowing for precise brain tissue ablation. NeuroOne aims to provide minimally invasive and effective solutions for patients suffering from epilepsy, Parkinson's disease, and other neurological conditions.

Is NMTC stock a good buy?

NMTC stock presents a speculative investment opportunity with high potential upside and significant risks. The company's innovative thin-film electrode technology and strategic partnership with RBC Medical Innovations are positive factors. However, the company's small market capitalization, negative P/E ratio, and limited commercialized products indicate financial challenges. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing. The potential for growth in the neurological disorder treatment market and the company's focus on minimally invasive solutions could drive future value, but successful commercialization and financial stability are critical for long-term success.

What are the main risks for NMTC?

NeuroOne Medical Technologies Corporation faces several key risks. Competition from larger, more established medical device companies is a significant threat. Regulatory hurdles and delays in obtaining approvals for new products could impede commercialization efforts. The company's dependence on strategic partnerships for product development exposes it to risks associated with partner performance and collaboration. Financial losses and the need for additional funding could dilute existing shareholders. Furthermore, the potential for product liability claims poses a risk to the company's financial stability and reputation. Investors should carefully assess these risks before investing in NMTC.

Is NMTC a good stock to buy?

Whether NMTC is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the NMTC MoonshotScore?

The MoonshotScore for NMTC is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is NMTC data updated?

NMTC stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to NMTC is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for NMTC?

Growth catalysts for NeuroOne Medical Technologies Corporation (NMTC) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes NeuroOne Medical Technologies Corporation's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are NMTC's main competitors?

NeuroOne Medical Technologies Corporation (NMTC) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether NMTC has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about NMTC?

Wall Street analyst coverage for NMTC includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is NMTC's market cap?

Market capitalization (market cap) for NMTC is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows NMTC's current market cap alongside enterprise value and other valuation metrics.

How has NMTC stock performed recently?

NMTC's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing NMTC's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in NMTC?

Key risk categories for NMTC include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures NMTC's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling NMTC?

Insider trading activity for NMTC tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is NMTC a good stock for beginners?

NeuroOne Medical Technologies Corporation (NMTC) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is NMTC for first-time investors?

Every stock carries risk, including NeuroOne Medical Technologies Corporation (NMTC). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NMTC.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
  • Forward-looking statements are subject to risks and uncertainties.
Data Sources
profilefundamentalsexistingCopy